Brentuximab Vedotin effects on prognosis of refractory and relapsed peripheral T-Cell lymphoma: a systematic review

Lucas Soares Bezerra, Marcelo Antônio Oliveira Santos-Veloso, Marinus de Moraes Lima


Brentuximab vedotin is a monoclonal anti-CD30 antibody-drug conjugate used to treat some cases of non-Hodgkin lymphoma. In this systematic review, we intend to analyze specifically the brentuximab on the treatment of refractory and relapsed peripheral T-cell lymphoma. Methods: PRISMA protocol for systematic reviews was used. The search was performed on Pubmed, Cochrane and Scielo employing the terms “Brentuximab” and “Peripheral T-cell Lymphoma” from November 2007 to November 2017. The clinical trials were individually assessed by the Cochrane Criteria Score and the systematic reviews by the Quality Assessment of Systematic Reviews and Meta-Analyses Score. Results: Heterogeneous results were found on CD30-positive patients treated with brentuximab vedotin as single-therapy, but the response was better on remission cases and presented longer free-survival time when combined with chemotherapy. Conclusions: Brentuximab vedotin is associated with beneficial results in the treatment of refractory and relapsed peripheral T-cell lymphomas in comparison with front-line therapy.

Texto completo:

PDF (English)